PerkinElmer Q3 Earnings, FY21 Guidance Beat Wall Street Expectations

Loading...
Loading...
  • PerkinElmer Inc's PKI Q3 revenues increased 21% Y/Y (12% organic) to $1.17 billion, beating the consensus of $1.04 billion.
  • Diagnostics segment posted $654 million in revenues, +21% (13% organic). Discovery & Analytical Solutions sales increased 21% (10% organic) to $513 million.
  • On the conference call, PerkinElmer President and CEO Prahlad Singh noted that non-COVID-19-related revenues grew 16% Y/Y organically, above the 12% forecast initially a quarter ago. COVID-19-related revenues "came in close to twice our expectations as testing remained similar to the levels we experienced in our second quarter."
  • CFO Jamey Mock added that COVID-related business generated about $300 million in revenues. Of that, about $170 million came from core products, with the balance resulting from PerkinElmer's COVID-19-related lab services.
  • PerkinElmer posted an adjusted EPS of $2.31, easily beating the consensus estimate of $1.71 and higher than $2.09 posted a year ago.
  • The firm finished Q3 with $487.4 million in cash and cash equivalents.
  • Guidance: For Q4, PerkinElmer forecast revenues of $1.2 billion and adjusted EPS of 2.05, compared to a consensus of $1.07 billion and $1.74, respectively.
  • PerkinElmer raised its FY21 forecast for revenue to $4.9 billion from a prior estimate of $4.57 billion, better than the consensus of $4.65 billion. 
  • It also increased its adjusted EPS forecast to $10.81 (consensus $10.07) from an earlier estimate of $9.88.
  • Price Action: PKI shares are trading lower by 2.26% at $172.32 on the last check Wednesday.
Loading...
Loading...
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...